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166 Am J PBackground: Treatment of periodontal (gum) disease may lessen the adverse consequences of
some chronic systemic conditions.
Purpose: To estimate the effects of periodontal therapy on medical costs and hospitalizations
among individuals with diagnosed type 2 diabetes (T2D); coronary artery disease (CAD); cerebral
vascular disease (CVD); rheumatoid arthritis (RA); and pregnancy in a retrospective observational
cohort study.
Methods: Insurance claims data from 338,891 individuals with both medical and dental insurance
coverage were analyzed in 2011–2013. Inclusion criteria were (1) a diagnosis of at least one of the ﬁve
speciﬁed systemic conditions and (2) evidence of periodontal disease. Subjects were categorized
according to whether they had completed treatment for periodontal disease in the baseline year,
2005. Outcomes were (1) total allowed medical costs and (2) number of hospitalizations, per
subscriber per year, in 2005–2009. Except in the case of pregnancy, outcomes were aggregated
without regard to reported cause. Individuals who were treated and untreated for periodontal disease
were compared independently for the two outcomes and ﬁve systemic conditions using ANCOVA;
age, gender, and T2D status were covariates.
Results: Statistically signiﬁcant reductions in both outcomes (po0.05) were found for T2D, CVD,
CAD, and pregnancy, for which costs were lower by 40.2%, 40.9%, 10.7%, and 73.7%, respectively;
results for hospital admissions were comparable. No treatment effect was observed in the RA cohorts.
Conclusions: These cost-based results provide new, independent, and potentially valuable evidence
that simple, noninvasive periodontal therapy may improve health outcomes in pregnancy and other
systemic conditions.
(Am J Prev Med 2014;47(2):166–174) & 2014 American Journal of Preventive Medicine
Open access under CC BY-NC-ND license.IntroductionThere is a growing body of evidence that perio-dontal (gum) disease is associated with negativesystemic health consequences for individuals
with certain diseases and conditions. To the extent that
this is true, it is reasonable to expect that successful
treatment of periodontal disease might prevent or
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Open access umedical conditions such as type 2 diabetes (T2D);
rheumatoid arthritis (RA); cerebral vascular disease
(CVD); and adverse pregnancy outcomes.
Direct conﬁrmation of such links generally poses
formidable difﬁculties arising from the long time course
of chronic disease, the complex and multifactorial nature
of the medical outcomes, and the ethical issues surround-
ing controlled clinical trials. Nevertheless, the potential
preventive value of such a simple and low-risk inter-
vention as dental hygiene in the management of patients
with serious medical conditions justiﬁes efforts to deter-
mine whether, and to what degree, a causal link exists.
Periodontal disease is a chronic inﬂammatory disease
in which a pathogenic bacterial bioﬁlm develops on the
tooth root surface in a susceptible patient. If untreated, it
can lead to alveolar bone resorption, infection, and tooth
loss. It has been suggested that periodontal disease may
also have an impact on systemic health via disseminationrican Journal of Preventive Medicine  Published by Elsevier Inc.
nder CC BY-NC-ND license.
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nation thereof. The deep pockets that are often present in
untreated patients with periodontal disease offer a favor-
able environment for proliferation of pathogenic plaque
bacteria and facilitate entry of bacteria and bacterial
products into the bloodstream of otherwise apparently
healthy patients via ulcerated and inﬂamed tissues.
Elevated serum levels of inﬂammatory mediators such
as tumor necrosis factor–alpha, interleukin (IL)-6, IL-1β,
prostaglandin E2, and C-reactive protein are a conse-
quence. Systemic effects are believed to arise from some
combination of disseminated toxins, bacterial insult, and
the actions of both innate and adaptive immunity. The
exact connections between oral and systemic disease,
however, remain complex and obscure. It is most
probable that the causal agents and mechanisms differ
among and within oral–systemic disease pairs. Tonetti
and Kornman1 provide a comprehensive review of
current knowledge about the oral–systemic link.
Treatment of periodontal disease can be as simple as
cleaning the teeth above and below the gum line, termed
“scaling and root planing” (SRP), which is sometimes
augmented by use of an antimicrobial mouthrinse. In
more advanced cases, periodontal surgery may also be
required. Such procedures aim to reduce gingival inﬂam-
mation, thereby reducing bacterial bioﬁlms on the tooth
and root surface, ultimately leading to a reduction of both
bacterial populations and transmission of bacteria and
toxins through the gingival tissue.
In the case of pregnancy, there is credible evidence
linking periodontal disease to spontaneous preterm birth
(sPTB). Although intervention studies have had mixed
results, several studies2,3 indicate that among women
with moderate to severe periodontal disease, simple
conventional therapies such as SRP with or without
antimicrobial mouth rinse4 can signiﬁcantly reduce the
incidence of sPTB. Further, it has been found that
successful periodontal treatment is strongly correlated
with full-term birth.5
In contrast to pregnancy, which is inherently time-
limited and has quantiﬁable outcomes such as birth
weight and gestational age, the other medical conditions
examined here are chronic, developing and persisting
over many years, and manifest as complex constellations
of symptoms. Nevertheless, associations have been
reported between periodontal disease and T2D,6,7
CVD,8–10 coronary artery disease (CAD),8,11 and RA.12
Double-blind clinical intervention trials have been con-
ducted, typically employing laboratory test values as
surrogates for morbidity (e.g., glycosylated hemoglobin
levels in diabetic patients13).
It is important to clarify whether, in what circum-
stances, and to what extent periodontal disease impactsAugust 2014general health. Controlled intervention trials would be
ideal, but large clinical trials in chronic conditions pose
practical difﬁculties, especially when endpoints of inter-
est are direct health outcomes as opposed to indirect
markers and surrogate measures. Consequently, the
evidence concerning the systemic effect of periodontal
disease on health remains inconclusive.
This retrospective intervention cohort study drew on
insurance records to explore possible associations
between periodontal therapy and medical costs and
hospitalizations. These outcomes are not only important
in themselves but also as plausible surrogates for the
severity of systemic disease.
The work reported here is a retrospective study
designed to test the hypothesis that treatment of perio-
dontal disease reduces medical costs and inpatient hospital
admissions during the 5 years after periodontal treatment
in individuals with ﬁve systemic medical diseases or
conditions: T2D, CAD, CVD, RA, and pregnancy.
Methods
Data Sources
Dental insurance claims data were obtained from United
Concordia Companies, Inc. (UCCI, Harrisburg PA), and
medical claims were obtained from Highmark, Inc. (Pittsburgh
PA). These afﬁliated companies share a common data manage-
ment system with common patient identiﬁers. Individually
identiﬁable information was stripped from the data before
transmission to the investigators. The study was submitted to
the University of Pennsylvania IRB, which issued a letter of
exemption.
Inclusion Criteria
From the uniﬁed database, subjects were selected who satisﬁed all
of the following conditions:1. Were enrolled in both a UCCI dental plan and Highmark
medical plan in calendar year 2005 (the baseline year, Year 0);2. Remained simultaneously and continuously enrolled in both
plans for at least 1 succeeding year (i.e., 2006);3. Received at least one covered visit for periodontal treatment or
maintenance in the baseline year, as evidenced by the corre-
sponding Current Dental Terminology (CDT)-5 codes
(Table 1);4. Had no recorded evidence of periodontal treatment in 2004,
thus ensuring that initial treatment, if any, occurred in
2005; and5. Experienced at least one completed pregnancy in the period
2005–2009, or, as of 2005, had a diagnosis of one or more
speciﬁed systemic condition (T2D, CAD, CVD, or RA).
Individuals who at any time in the 2005–2009 interval ceased to
be covered under either or both plans were excluded from analysis
in subsequent years and not re-entered.
Table 1. Medical and dental insurance codes used in the study
Condition/treatment Standard Applicable codes
Dental: periodontal therapy
Treatment for periodontitis or gingivitis CDT-5 D4210, D4211, D4240, D4241, D4245, D4260,
D4261, D4263, D4264, D4265, D4266, D4267,
D4274, D4341, D4342, D4381
Maintenance D4910
Prophylaxis D1110
Chronic medical conditions
Type 2 diabetes ICD-9 250–25099, 3572–35729, 3620–36209,
36641, 6480
Cerebral vascular disease 433, 434
Coronary artery disease 411, 413, 414, 4292
Rheumatoid arthritis 7140, 7141, 7142, 71481
Pregnancy and delivery
Supervision of high-risk pregnancy ICD-9 V23
Treatment incidental to pregnant state V22.2
CDT-5, Current Dental Terminology, 5th Edition
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Subjects whose insurance records indicated the presence of any of
four chronic systemic disease conditions—T2D, CVD, CAD, or
RA—were identiﬁed on the basis of corresponding ICD-9 codes
(Table 1), as were pregnant women receiving prenatal and
perinatal care. A subject whose record showed one or more
suitably coded encounters in the baseline year (2005) was
construed as having the relevant condition throughout the study
period, regardless of whether the codes recurred in subsequent
years. Treatment for pregnancy was treated not as a chronic
disease, but as an event recorded in the year(s) in which it
occurred. These medical conditions are not mutually exclusive;
therefore, a client with complicated medical conditions would be
included in multiple cohorts.
Determination of Treatment Threshold
For any yes/no decision rule, a receiver operating characteristic
(ROC) deﬁnes the tradeoff between sensitivity and speciﬁcity as a
function of some threshold parameter.14 Here, the demarcation
between treated and untreated groups was determined by applying
ROC analysis to all subjects meeting the inclusion criteria, where
the dichotomous outcome was deﬁned as one or more hospital-
izations in 2007, and the level of treatment as the number of
periodontal visits in 2005.
A threshold of four visits in 2005 optimized discrimination
between outcomes based on periodontal treatment intensity, and
was subsequently taken as the deﬁnition of completed treatment
throughout the study. This level happens to coincide with the
typical recommended course of therapy for moderate to severe
periodontitis.Measures
Outcome measures. For each treatment group, each medical
condition, and each study year (2005–2009), two outcomes
(dependent variables) were calculated from the database:1. Primary outcome: the mean total annual covered medical
(non-dental) costs per client, inpatient, and outpatient; in the
case of pregnancy, only those costs incidental to pregnancy
(ICD code V22.2) and for supervision of high-risk pregnancy
(V23); for other conditions, all costs irrespective of cause; and2. Secondary outcome: the annual number of hospitalizations per
thousand clients, irrespective of cause (not computed for
pregnancy).
Independent variable. All qualifying subjects were deemed to
have been diagnosed with periodontal disease by a licensed
professional, by virtue of the inclusion criteria. They were further
categorized into two groups: (1) the treated group, who received
follow-up treatment (deﬁned as having at least four visits in calendar
year 2005 with the aforementioned CDT-5 codes), and (2) the
control group, comprising subjects who elected to remain untreated.
Covariates. Client age, gender, and T2D status were taken as
covariates for all analyses except where redundant. Other poten-
tially useful factors, such as laboratory values and observations
recorded during medical and dental examinations, were not
available from the database. Post hoc analysis, however, provided
strong evidence that the treatment and control groups did not
differ signiﬁcantly in the baseline year with respect to medical cost,
the primary study outcome.www.ajpmonline.org
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according to the calendar year in which the services were provided.
Costs are in current U.S. dollars, and there was no correction for
partial-year enrollment. For technical reasons, total medical costs
were not available for 2006 (Year 1) for subjects with CVD, CAD,
and RA.
Statistical Analysis
ANCOVA was used to assess the effect of periodontal treatment
after accounting for the three covariates (age, gender, and T2D
status). Statistical signiﬁcance was based on Wilks’s lambda, using
a po0.05 threshold. The signiﬁcance of year by year differences
was assessed by collapsing over the covariates, and applying
Welch’s t-test, again with a threshold of po0.05. Analysis began
in 2011 and ended in 2013. Figure 1 depicts the ﬂow of data
selection and analysis.
The decision to present only T2D status as a comorbidity
factor was based on preliminary analyses in which ANCOVA
was applied in turn, treating each of the other conditions as aCompare medic
admissions for
(A
1, 2, or 3
(control group)
Medical and d
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One or
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No visit
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Numbe
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Figure 1. Simpliﬁed sequence of data selection and analysis
Note: X denotes one of the following systemic conditions: Type 2 diabetes, co
Pregnancy need not occur in the baseline year.
August 2014covariate (i.e., ten analyses). Only in the case of T2D did the
contribution of the second systemic condition approach stat-
istical signiﬁcance.
Results
Sample characteristics and results are summarized in
Tables 2 (pregnancy) and 3 (chronic diseases). From a
database of individuals with qualifying medical and
dental insurance, 338,891 satisﬁed the inclusion criterion
for periodontal disease. These qualifying subjects were
45% women and 55% men; mean age was 48.7 (10.9)
years. They were grouped into cohorts based on systemic
condition and periodontal treatment.
The tables show subject count in the baseline year
(2005); because some individuals terminated medical or
dental coverage at some time during the study period, the
size of each cohort generally decreased monotonicallyal costs and hospital
 the period 2006–2009
NCOVA)
ental insurance in 2005
emic condition "X" in 2005
 more visits for
tal disease in 2005
s for periodontal
ease in 2004
r of periodontal
e visits  in 2005
4 or more
(treatment group)
al costs and hospital
ach year, 2005–2009
h's t test)
ronary artery disease, cerebral vascular disease, or rheumatoid arthritis.
Table 2. Pregnancy: comparison of costs for atypical encounters
Pregnancy and delivery (atypical encounters)
First pregnancy 2005–2009 Second pregnancy 2005–2009
Periodontal treatment
Total number of qualifying subjects in Year 0 (2005) 8,342 2,536
ICD-9 codes for inclusion in cohort V22.2, V23
Periodontal treatment received Untreated Treated Untreated Treated
Number in cohort 8,320 22 2,531 5
Percentage periodontally treated 0.3% 0.2%
OUTCOMES
Total medical costs
Total medical costs per subject per pregnancy $3,299 $866 $3,301 $1,754
Annual reduction with treatment $2,433 (73.7%) $1,547 (46.9%)
Signiﬁcance, Wilks’s lambda po0.001 NS
Hospital admissions N/A N/A
Note: Differences signiﬁcant at the po0.05 level are shown in boldface.
N/A, not applicable; NS, not signiﬁcant
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(approximately 1%) of patients diagnosed with perio-
dontal disease received treatment by the rather stringent,
but clinically realistic, criterion employed (i.e., four visits
in 2005).
The cost and admissions savings reported in Table 3
are averages taken over the 4-year post-treatment period,
2006–2009. There was no signiﬁcant difference in the
case of RA, but all the remaining associations were
signiﬁcant at the po0.05 level.
In contrast to the other systemic conditions, where
outcomes were aggregated without regard to reported cause,
the costs for only two pregnancy-related treatment codes
were included in the analysis (V22.2, treatment incidental to
pregnancy, and V23, supervision of high-risk pregnancy).
These constitute atypical, rather than total, costs of
pregnancy. For these components, the cost impact was
especially large, with a 74% difference for the ﬁrst delivery.
Because only ﬁve subjects had two pregnancies during the
period, the observed cost difference for the second instance,
though large, was not statistically signiﬁcant.
Figure 2 shows the mother’s costs for atypical preg-
nancy care only; Figure 3 presents year-by-year results
for T2D, CVD, CAD, and RA. In all cases, the untreated
group appears in broken, and the treated group in
continuous, lines. Solid markers indicate that the then-
year difference was signiﬁcant at the po0.05 level
(Welch’s t test), whereas hollow markers indicate a lack
of statistical signiﬁcance. Because these year-by-year tests
compare only the two intervention groups and collapsethe covariates, they are not simply related to the
ANCOVA results.
Patients with diabetes or CVD showed large (around
20%–40%) and signiﬁcant reductions in both outcomes
relative to controls, which appeared to persist up to 3
years after initial periodontal therapy. In the case of CAD
patients, the number of hospitalizations showed a similar
trend, although cost differences appeared less pro-
nounced and of varying signiﬁcance over time. The
absence of an effect in RA was noted.
Discussion
This study shows lower medical costs and hospital-
izations in the time period following periodontal treat-
ment in patients in four of the ﬁve conditions examined
(T2D, CVD, CAD, and pregnancy), when compared to
untreated controls. In each case, the difference is both
statistically signiﬁcant and substantial in magnitude
(11%–74% lower in the treated group). The absence of
a corresponding effect in RA is intriguing. Unlike the
other systemic conditions, RA is clearly known15 to be at
its core an autoimmune inﬂammatory disease, which
may help account for this marked difference in outcomes.
Although the intergroup comparisons are clear, they
cannot answer the crucial question of whether differences
are caused by periodontal therapy or whether a patient’s
completion of periodontal therapy arises from a complex
of factors that tend to improve health outcomes irre-
spective of periodontal disease. Some insight can bewww.ajpmonline.org
Table 3. Chronic medical conditions: comparison of costs and hospitalizations
Chronic systemic disease
Type 2 diabetes
Cerebral vascular
disease
Coronary artery
disease
Rheumatoid
arthritis
Periodontal treatment
Total number of qualifying
subjects in Year 0 (2005)
91,242 13,007 8,458 81,439
ICD-9 codes for inclusion in
cohort
250–25099, 3572–
35729, 3620–
36209, 36641, 6480
433, 434 411, 413, 414, 4292 7140, 7141, 7142,
71481
Periodontal treatment received Untreated Treated Untreated Treated Untreated Treated Untreated Treated
Number in cohort 90,329 913 12,868 139 8,368 90 80,903 536
Percentage periodontally treated 1.0% 1.1% 1.1% 0.7%
OUTCOMES
Total medical costs
Total medical costs per subject
per year (mean 2006–2009)
$7,056 $4,216 $13,895 $8,214 $10,222 $9,133 $9,218 $8,637
Annual reduction with
treatment
$2,840 (40.2%) $5,681 (40.9%) $1,090 (10.7%) $581 (6.3%)
Signiﬁcance, Wilks’s lambda po0.04 po0.04 po0.04 NS
Hospital admission
Inpatient admissions per
1,000 subjects per year (mean
2006–2009)
66.6 40.4 444.4 350.0 65.2 46.6 142.7 136.3
Annual reduction with
treatment
26.3 (39.4%) 94.4 (21.2%) 18.7 (28.6%) 6.4 (4.5%)
Signiﬁcance, Wilks’s lambda po0.05 po0.002 po0.01 NS
Note: Differences signiﬁcant at the po0.05 level are shown in boldface.
NS, not signiﬁcant
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Figure 2. Atypical pregnancy and delivery cost by period-
ontal treatment group
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outcomes, but the present evidence is mixed.
In all cases, costs for the treatment and non-treatment
groups are statistically indistinguishable in the baseline
year, consistent with the hypothesis that there is no
unmodeled common causal factor. The same is true for
hospitalizations (the secondary outcome) in all cases except
CAD, where the roughly parallel time courses suggest that
the observed differences could be due to an unmodeled
confounder rather than periodontal treatment itself.
The question of causality, therefore, must remain open
pending prospective randomized intervention trials.
Although this research provides no insight into the exact
nature, much less the cause, of the observed differences,
total per capita medical costs and number of hospital-
izations are reasonable surrogates for a wide spectrum
of health outcomes, including but not limited to those
directly associated with the underlying medical
condition.August 2014In a “bounding” study such as this with a high degree
of data aggregation (as to time, treatment, and diagno-
ses), absence of a signiﬁcant correlation would not be
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Figure 3. Medical cost and number of hospitalizations by periodontal treatment group
Note: Points offset horizontally for clarity.
Error bars are  1 SE.
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against an oral–systemic link in speciﬁc conditions and
medical outcomes. On the other hand, the statistically
signiﬁcant relationships reported here are strongly sug-
gestive of an underlying biomedical link, irrespective of
the mechanisms and causal chains that might drive it.Strengths and Limitations
The strengths and weaknesses of this research are worth
noting. On the positive side, the design is a true inter-
vention study, as cohorts were deﬁned solely on the basis of
a particular treatment and followed thereafter. On the
other hand, it lacks the prospective, controlled, blinded,
and balanced properties that yield the strongest clinical
evidence achieved by a double-blind RCT. Moreover, the
approach is both indirect, to the extent that cost and
inpatient admissions are viewed as surrogates for general
health, and simpliﬁed in that data were aggregated by
calendar year. Potentially informative but unavailable data
such as laboratory values could not be used as covariates.
The fact that U.S. dental insurance codes report only
procedures, not diagnoses, required that periodontal
disease status be indirectly inferred in this study.
Although this approach is valid, it is necessarily based
on a relatively broad-brush view of dental status. Explicit
dental diagnostic data would have enabled a more reﬁned
and potentially more informative analysis. Given the
obvious utility of diagnostic codes in both research and
patient care, it is difﬁcult to understand why they have
not been adopted in dentistry.
Although beyond the scope of the present study,
similar methods could be used to determine how cost
and hospitalization vary with the number of periodontal
visits deﬁned as “treated.” Such dose–response data
would provide valuable insight into beneﬁts derivable
from less-than-optimal patient adherence.
Health insurance records can be a rich source of
research data if careful steps are taken to protect patient
conﬁdentiality. From this starting point, analyses may
range from straightforward correlations to more elabo-
rate kinds of inference, of which the present work is a
modest example. Further explorations of this and other
databases are planned, using other strategies including
time-series analysis to increase the power and reﬁnement
of the results. As additional data elements (e.g., lab values
and dental diagnostic codes) become available, they will
be exploited. It is hoped that other investigators, with
access to other insured populations, will replicate and
extend the methods developed here.
Inherent limitations in the source data restricted
this study to only rudimentary demographic variables.
Many other factors—medical, behavioral, economic, andAugust 2014others—might be postulated in addition to periodontal
therapy to explain the observed differences between
groups. However, the fact that total medical costs did
not differ signiﬁcantly between groups in the baseline
year constitutes strong evidence that the net inﬂuence of
all unmodeled factors is insufﬁcient to require the
inclusion of further covariates in the model.
Implications for Disease Management and
Prevention
If evidence continues to accumulate that an oral–sys-
temic health link not only exists but also can be exploited
to improve general health, two important consequences
can be expected. Clinically, it would be logical for
assessment and treatment of periodontal disease to be
routinely considered in the management of speciﬁc
medical conditions. Scientiﬁcally, further research, clin-
ical and otherwise, could be better focused on the
underlying pathways and causal factors.
The ﬁndings to date certainly do not prove that
treatment of active periodontal disease has a beneﬁcial
effect beyond the mouth. However, they are entirely
consistent with such a hypothesis, and reinforce evidence
of other kinds and from other sources. Nevertheless,
simple periodontal treatment as examined here comes at
modest cost and minimal risk. Therefore, although its
interventional efﬁcacy remains open to debate, we
recommend that it be considered part of the preventive
armamentarium for chronic disease management.
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